Overview
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Lobbying Costs
None declared
Financial year: Jan 2020 - Dec 2020
Lobbyists (Full time equivalent)
0.8 Fte (5)
Lobbyists with EP accreditation
0
High-level Commission meetings
3
Lobbying Costs over the years
-
Info
Global Alliance for Tuberculosis Drug Development (TB Alliance)
EU Transparency Register
636752920377-18 First registered on 20 Jan 2016
Goals / Remit
TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.
Main EU files targeted
Innovation for global health research and development primarily in Horizon2020 and FP9. Ensure that TB product development is included in the new research framework for the EU, and that it specifically includes a well-funded mechanism (EDCTP and IMI) to ensure funding for product development and clinical trials.
Policy Files:
Proposal for a Council Regulation on the emergency framework regarding medical countermeasures & related HERA consultations
Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on Serious Cross-Border Threats to Health & consultation
Proposal for amending Regulation (EC) No 851/2044 establishing a European Centre for disease prevention and control & consultation
EU4Health 2022 Work Programme consultation
Revision of the genera pharmaceutical legislation consultation
Council Regulation establishing the Joint Undertakings under Horizon EuropeAddress
Head Office
40 Wall Street 24th Floor
New York 10005
UNITED STATESEU Office
40 Wall Street 24th Floor
New York 10005
UNITED STATESWebsite
-
People
Total lobbyists declared
5
Employment time Lobbyists 25% 2 10% 3 Lobbyists (Full time equivalent)
0.8
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 21 Jul 2022
Name Start date End Date Mr Willo BROCK 30 Aug 2019 29 Aug 2020 Ms Erin MORTON 24 Feb 2018 23 Feb 2019 Mr Willo BROCK 20 Jan 2018 19 Jan 2019 Complementary Information
Number of persons includes 2 staff/employees and 3 consultants.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
AMR Stakeholder Network - https://epha.org/amr-stakeholder-network/
Member organisations
- https://era4tb.org/about-imi/
- https://eu-pearl.eu/
- https://www.unite4tb.org/ -
Financial Data
Interests represented
Does not represent commercial interests
Closed financial year
Jan 2020 - Dec 2020
Lobbying costs for closed financial year
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Total organisational budget in closed year
70,000,000€
Major funding types in closed year
Grants
Major contributions in closed year
Type Name Amount Contribution Bill and Melinda Gates Foundation 19,000,000€ Contribution UK Foreign Commonwealth Development Office 11,000,000€ Contribution Australia Department of Foreign Affairs 9,100,000€ Major contributions in current year
Type Name Amount Grant UNITE4TB (IMI/IHI) 1,900,000€ Other financial info
TB Alliance is part of a consortium - UNITE4TB being funded under IMI/IHI AMR Accelerator mechanism.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
World TB Day activities around innovation in TB research. European Parliament meetings and events around health research and product development. In 2021, TB Alliance continued its EU advocacy focusing on the urgent need for R&D and medical products for neglected and (re) emerging diseases in light of the Covid pandemic and AMR.
As an Associated Partner and Funding Receiving Beneficiary in various IMI projects, TB Alliance has been actively participating in building EU R&D capacity through the AMR Accelerator Programme.
Additionally, we've also contributed towards:
Keeping the Promise report: https://www.keepingthepromisereport.org/
AMR Awareness WeekOther activities
None declared
- Meetings
Meetings
3 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 14 Oct 2022 Location Brussels Subject Global Gateway Strategy and Global Health Strategy Cabinet Cabinet of Commissioner Jutta Urpilainen Portfolio International Partnerships Attending - Renaud Savignat (Cabinet member)
-
Date 10 Oct 2018 Location Brussels Subject Global Health in Horizon Europe Cabinet Cabinet of Commissioner Carlos Moedas Portfolio Research, Science and Innovation Attending - Giulia Del Brenna (Cabinet member)
-
Date 25 Jan 2018 Location Brussels Subject EU action to help reduce TB Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Vytenis Andriukaitis (Commissioner)
- Paula Duarte Gaspar (Cabinet member)
Other Lobbyists
- Meetings